Steroid-enhancing selective casein kinase inhibitors: first in class novel inhaled anti-asthma agents

慢性肺部疾病降低了全球5亿人的生活质量和寿命（四分之一的澳大利亚人）。目前的药物不能充分减少肺功能的下降。这一进展是基于一种导致肺功能不良的酶途径的发现。该项目将确定药物的最佳剂量以及与现有药物的最佳组合，以减少肺部疤痕和炎症。这些新发现支持了确保临床试验投资的努力。

Chronic lung diseases reduce quality and duration of life of 0.5 billion globally (1 in 4 Australians). Current drugs fail to adequately reduce the decline in lung function. This development is based on the discovery of an enzyme pathway contributing to poor lung function. The project will identify the best doses of the drug and the best combinations with existing drugs to reduce the lung scarring and inflammation. These new findings support efforts to secure investment for clinical testing.